Springer Nature could launch IPO as soon as next week, sources say
By Emma-Victoria Farr
FRANKFURT, Sept 3 (Reuters) -German academic research publisher Springer Nature is planning to file documents next week announcing its listing plans, kicking off the European initial public offering (IPO) market for autumn, three people familiar with the matter told Reuters.
The company is likely to set out its intention to float on the Frankfurt Stock Exchange as soon as next week, the people said, speaking on condition of anonymity.
Reuters previously reported a deal could value the publisher of science journal Nature and Scientific American at up to 9 billion euros ($10 billion) including debt.
Springer Nature held meetings with investors last week and may opt for a smaller offering than originally planned, the people said.
Springer Nature's IPO plans will be watched closely as a string of companies plan listings in Europe, after other new offerings this year from Swiss skincare firm Galderma GALD.S and private equity firm CVC Capital Partners CVC.AS made gains for investors.
Shareholders Holtzbrinck Publishing Group and BC Partners own 53% and 47% stakes respectively.
The company may also decide against an IPO if markets are not conducive and volatility increases, the people said.
Springer Nature and BC Partners declined to comment. A spokesperson for Holtzbrinck was not immediately available for comment.
Springer Nature planned an IPO in 2020 but the COVID-19 pandemic forced it to postpone. Its financial leverage ratio has been reduced to 2.9 times in recent years, from 4.6 times in 2019, according to the company's annual report.
Reuters reported in February that BC Partners was in the early stages of studying options for its stake in Springer Nature, including a potential IPO of the business.
The company's peers include Dutch academic publisher Elsevier, owned by RELX REL.L, and research publisher Taylor & Francis, owned by Informa INF.L. Springer Nature publishes around 14,000 specialist books and 3,000 specialist journals.
Springer Nature was established in 2015, following the merger of Macmillan Science & Education and Springer Science + Business Media. It has headquarters in Berlin and operates research, education and health divisions, with over 9,000 employees in more than 40 countries.
($1 = 0.9038 euros)
Reporting by Emma-Victoria Farr; Editing by Anousha Sakoui and Mark Potter
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
